Elon Musk’s Neuralink has successfully implanted its brain chip in a second patient. The individual, suffering from a spinal cord injury, now has the potential to interact with digital devices solely through thought, marking a significant step forward in merging technology with human biology.
The Innovative Technology Behind the Chip
Neuralink’s neurochip is equipped with 400 electrodes, while the company claims the potential to use up to 1,024 electrodes for improved functionality. This advanced piece of technology functions as a capsule-receiver, which is placed behind the ear, much like a hearing aid. From the capsule, thread-like electrodes are inserted into the brain. These electrodes, thinner than a human hair, communicate directly with neural pathways, allowing for brain-computer interaction. Each implant can host up to 1,500 electrodes.
The processor, measuring a mere 4×4 mm, manages signals from approximately 10,000 electrodes, enabling precise and high-speed communication between the brain and digital devices. Such technology opens the door to innovations that could vastly improve the quality of life for paralyzed individuals and others with neurological challenges.
A Glimpse at Past Success and Challenges
The first patient to receive this technology was implanted with a brain chip in January 2024. After suffering paralysis from the shoulders down, the man could control video games, surf the Internet, and even engage on social media—entirely with his thoughts. Despite the success, the initial chip faced complications. A month after implantation, developers reported that the thin electrodes had shifted, causing signal disruptions.
This led Neuralink to adjust their approach for the second volunteer by embedding the chip deeper into the motor cortex to prevent similar issues. After receiving approval from the US Food and Drug Administration (FDA) in May, the second patient underwent the procedure successfully.
Neuralink’s Future Ambitions
Looking ahead, Neuralink aims to implant its devices in 10 more volunteers by the end of 2024. Additionally, the company is preparing to apply for clinical trials in Canada and the United Kingdom, as it continues its groundbreaking work in neural technologies.
For further details, visit the original source here.
